Comprehensive update on cannabis epidemiology, brain effects, and mental health risks
A review of cannabis research confirmed increasing global use with highest prevalence among youth, mechanism similarities with opiates, evidence supporting gateway drug concerns, and growing evidence linking use to psychotic disorders.
Quick Facts
What This Study Found
The review synthesized evidence across three domains. Epidemiologically, cannabis use typically starts between ages 15-24 and decreases with adult responsibilities. The highest prevalence is in North America, Australia, and Europe.
Neurobiologically, cannabis shares some mechanism-of-action analogies with opiates. Clinical evidence supports concerns about the increased consumption among youth and the risk of psychotic disorder onset.
The review stated that cannabis intake during adolescence "may facilitate the transition to the use and/or abuse of other psychotropic drugs, hence properly being considered a 'gateway drug.'" The authors concluded that the social perception of low risk is at odds with biological and clinical evidence of cognitive impairment and mental health effects.
Key Numbers
Cannabis use prevalence: varies by income, highest in North America, Australia, Europe. Typical initiation: ages 15-24. Use decreases with acquisition of adult responsibilities.
How They Did This
Narrative review examining papers on epidemiological, neurobiological, and psychopathological aspects of cannabis use, searched through PubMed.
Why This Research Matters
This review captures the tension between rising social acceptance and accumulating scientific evidence of harm, particularly for young users. The neurobiological parallels with opiates and the gateway drug discussion add important context to ongoing policy debates.
The Bigger Picture
The disconnect between public perception ("soft drug") and scientific evidence (cognitive impairment, psychosis risk, gateway effects) represents one of the central challenges in cannabis policy. This review highlights that the evidence for harm has grown even as social acceptance has increased.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. The gateway drug framing is contested in the research community. The review does not adequately distinguish between moderate and heavy use in its risk assessments. Published in a pharmacology journal, which may emphasize biological concerns over social context.
Questions This Raises
- ?How does the risk profile change with different use patterns (occasional vs daily)?
- ?Do harm reduction approaches (lower potency, non-smoked routes) meaningfully reduce the risks described?
- ?Can the gateway drug effect be explained by shared predisposing factors rather than cannabis itself?
Trust & Context
- Key Stat:
- Social perception of low risk conflicts with biological evidence of cognitive and mental health harm
- Evidence Grade:
- Narrative review covering multiple research domains. Provides a useful overview but lacks systematic rigor and may overstate certain conclusions.
- Study Age:
- Published in 2017. The epidemiological landscape has continued to shift with legalization in multiple countries.
- Original Title:
- Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update.
- Published In:
- CNS & neurological disorders drug targets, 16(5), 598-609 (2017)
- Authors:
- De Luca, Maria Antonietta(7), Di Chiara, Gaetano(3), Cadoni, Cristina(2), Lecca, Daniele, Orsolini, Laura, Papanti, Duccio, Corkery, John, Schifano, Fabrizio
- Database ID:
- RTHC-01363
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is cannabis really a gateway drug?
This review supports the gateway drug characterization, citing evidence that adolescent cannabis use facilitates transition to other drug use. However, this is a contested interpretation in the scientific community. Alternative explanations include shared genetic vulnerability, common social environments, and the broader availability of other drugs in cannabis-using networks.
How does cannabis compare to opiates neurobiologically?
The review noted mechanism-of-action analogies between cannabis and opiates, meaning some of the brain pathways affected overlap. However, this does not mean cannabis is as addictive or dangerous as opiates. The overlap exists at the level of reward and dependence circuitry.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-01363APA
De Luca, Maria Antonietta; Di Chiara, Gaetano; Cadoni, Cristina; Lecca, Daniele; Orsolini, Laura; Papanti, Duccio; Corkery, John; Schifano, Fabrizio. (2017). Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update.. CNS & neurological disorders drug targets, 16(5), 598-609. https://doi.org/10.2174/1871527316666170413113246
MLA
De Luca, Maria Antonietta, et al. "Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update.." CNS & neurological disorders drug targets, 2017. https://doi.org/10.2174/1871527316666170413113246
RethinkTHC
RethinkTHC Research Database. "Cannabis; Epidemiological, Neurobiological and Psychopatholo..." RTHC-01363. Retrieved from https://rethinkthc.com/research/de-2017-cannabis-epidemiological-neurobiological-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.